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Introduction
Th  e idiopathic inﬂ   ammatory myopathies (IIMs) poly-
myo  sitis (PM) and dermatomyositis (DM) are hetero-
geneous conditions that are historically diagnosed by 
proximal muscle weakness, evidence of muscle inﬂ  am-
ma  tion or necrosis, and characteristic skin lesions [1,2]. 
However, it is now well recognized that patients can 
present with other overlapping features, including 
arthritis and systemic involvement (including interstitial 
lung disease, or ILD), and this has led to the proposal of 
alternative diagnostic criteria [3]. In recent years, it has 
become even more apparent that autoantibodies have a 
role in distinguishing between further subtypes of 
myositis patients, and clinico-serological classiﬁ  cations 
have been proposed. Th   e myositis autoantibodies can be 
divided into myositis-associated autoantibodies (MAAs) 
and myositis-speciﬁ   c autoantibodies (MSAs). Th  e 
MAAs  – anti-PMScl, anti-Ku, anti-U1RNP, and anti-
U3RNP (ﬁ  brillarin) – are commonly found in myositis 
patients who have features of other connective tissue 
diseases (CTDs) (in particular, overlap with systemic 
sclerosis). In contrast, the MSAs are found exclusively in 
IIM and are directed to speciﬁ  c proteins found in both 
the nuclear and cytoplasmic regions of the cell; these 
MSAs correlate with genotype and clinical manifestations 
[4,5]. Investigations into these speciﬁ  c  auto  antibodies 
help classify myositis patients into increasingly homo  ge-
neous subgroups, may guide speciﬁ  c treatment regimes, 
and importantly increase our understanding of the 
patho  genesis of IIM.
Th  e ‘traditional’ MSAs – anti-Jo-1 (and the less 
common non-Jo-1 anti-synthetases), anti-SRP, and anti-
Mi-2 – can be detected by routine commercial assays and 
are identiﬁ   ed in approximately 40% to 50% of adult 
myositis patients and in less than 10% of juvenile 
dermato  myositis (JDM) patients [6]. More recently, a 
number of groups have reported the identiﬁ  cation  of 
novel MSAs, including anti-p155/140, anti-SAE, anti-
CADM-140 (melanoma diﬀ  erentiation-associated gene 5, 
or MDA5), anti-p140, and anti-200/100, the clinical and 
genetic associations of which are described in this review. 
With the inclusion of the latter MSAs, it is now possible 
to identify a positive MAA or MSA in approximately 80% 
of myositis patients, allowing a clearer serological 
stratiﬁ  cation of patients (Table 1 and Figure 1).
Anti-synthease syndrome
Anti-synthetase autoantibodies
Th   e most prevalent group of MSAs consists of the anti-
synthetase autoantibodies. Th  ese autoantibodies target 
the amino-acyl-tRNA synthetases (ARSs) which catalyze 
the binding of amino acids to the corres  ponding tRNAs. 
Each amino acid has a separate ARS, and autoantibodies 
targeting 8 of the 20 ARSs have been identiﬁ  ed. Th  e  most 
common of these is anti-Jo-1 (anti-histidyl tRNA synthe-
tase), which is found in approximately 20% of adult IIM 
patients. Th   e remaining anti-synthetases – PL-12 
(alanyl), PL-7 (threonyl), EJ (glycyl), OJ (isoleucyl), KS 
(asparginyl), and the more recently identiﬁ  ed Ha (tyrosyl) 
and Zo (phenylalanyl) – have been collectively described 
in a further 20% of patients, and the frequency of each 
individual auto  antibody is between 1% and 5% [4]. In 
contrast, the prevalence of ASAs in juvenile myositis 
patients is much lower: less than 3% [7]. With a few 
exceptions, each ASA-positive patient develops 
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auto  anti  bodies are classed as having the anti-synthetase 
syn  drome (ASS) with clinical associations of myositis, ILD, 
non-erosive arthritis, mechanic’s hands, Raynaud pheno-
menon, and fever, and some patients also have a DM rash.
Th  e presence of an ASA has also been shown to 
indicate response to corticosteroid treatment, particu  larly 
in the context of ILD, with ASA-positive patients 
responding better to initial therapy but having relapses 
more frequently than ASA-negative patients [8]. Further-
more, it has been demonstrated that titers of anti-Jo-1 
autoantibodies moderately correlate with serum creatine 
kinase levels as well as joint and muscle disease activity 
[9], demonstrating that the presence and titer of MSAs 
can help predict disease course and treatment response.
Recently, it has been shown that, while the ASS covers 
all eight anti-synthetase autoantibodies, the precise 
clinical manifestations associated with each autoantibody 
are not identical. It has been reported that anti-Jo-1 
autoantibodies are closely associated with what would be 
classically described as PM, with the majority developing 
clinically signiﬁ  cant myositis over the full disease course 
[10]. In comparison, anti-OJ, anti-KS, and anti-PL-12 
have been more closely associated with DM skin lesions 
and are strongly associated with ILD. Th   e development of 
clinically evident myositis in these patients is less 
frequent than with anti-Jo-1 and often occurs after the 
onset of ILD [11-13]. In addition, patients with anti-PL-7 
may have lower serum muscle enzyme levels and milder 
muscle weakness in comparison with anti-Jo-1 patients 
[14].
Anti-Ha, the seventh ASA to be identiﬁ  ed, was identi-
ﬁ  ed by means of a combination of immunoaﬃ   nity puriﬁ  -
cation and mass spectrometry. So far, it has been 
demonstrated in only one patient who displayed clinical 
manifestations of ILD and myositis [15]. Anti-Zo, the 
most recent ASA to be identiﬁ   ed, was identiﬁ  ed  by 
means of immunoprecipitation (IPP) and mass spectro-
metry. It was ﬁ  rst detected in an index case with myositis 
and ILD [16] and has since been found in a further three 
patients with classic ASS features (ZEB and NJM, 
unpublished data).
Further studies have been completed on the pathogenic 
roles of the ASAs and their corresponding autoantigens. 
Seminal work by Casciola-Rosen and colleagues [17] has 
shown that Jo-1 autoantigen expression is enhanced in 
the muscle of myositis patients in comparison with 
normal controls, suggesting a role for autoantigens in the 
Table 1. Myositis-specifi  c autoantibodies, target autoantigens, and clinical associations
Frequency, percentage
Autoantibody Target autoantigen Clinical associations Adults JDM
Anti-ARS
- Jo-1
- PL7
- PL12
- OJ
- EJ
- KS
- Ha
- Zo
Amino-acyl-tRNA synthetase
- Histidyl
- Theronyl
- Alanyl
- Isoleucyl
- Glycyl
- Asparaginyl
- Tyrosyl
- Phenylalanyl
Anti-synthetase syndrome
Myositis
Interstitial lung disease
Raynaud phenomenon
Arthritis
Mechanic’s hands
Fever
Overall: 30-40
Jo-1: 15-20
PL7: <5
PL12: <5
OJ: <5
EJ: <5
KS: <5
Ha: <1
Zo: <1
Overall: 1-3
Anti-Mi-2 Nucleosome remodeling deacetyalse 
complex (NuRD)
DM <10 4-10
Anti-p155/140 Transcriptional intermediary factor 1 
gamma (TIF1-γ)
JDM: DM and ulceration
Adults: DM and malignancy
13-21 22-29
Anti-p140 Nuclear matrix protein 2 (NXP2) JDM: DM and calcinosis
Adults: DM and ILD
<5 23
Anti-SAE Small ubiquitin-like modifi  er activating 
enzyme (SAE)
DM <5 <1
Anti-CADM-140 Melanoma diff  erentiation-associated 
gene 5 (MDA5)
CADM and ILD 50-73 CADM (not in Caucasians) Not known
Anti-SRP Signal recognition particle (SRP) Necrotizing myopathy 5-10 <3
Anti-200/100 Unknown 100- and 200-kDa proteins Necrotizing myopathy <10 necrotizing myopathy Not known
ARS, amino-acyl-tRNA synthetase; CADM, clinically amyopathic dermatomyositis; DM, dermatomyositis; ILD, interstitial lung disease; JDM, juvenile dermatomyositis. 
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ARSs can be cleaved by granzyme B which may reveal 
autoantigenic epitopes [18], and Levine and colleagues 
[19] demonstrated that the cleavable conformation of 
Jo-1 is found predominantly in alvelolar cells, suggesting 
that the lung microenvironment is the site of disease 
initiation in the Jo-1 syndrome. Further work has shown 
that Jo-1, KS, and Ha autoantigens have chemoattractant 
properties and can induce leukocyte migration, hence 
potentially propagating the immune response [20]. A 
study by Barbasso Helmers and colleagues [21] demon-
strated that serum from anti-Jo-1-positive patients had a 
signiﬁ  cantly stronger eﬀ  ect on the expression of inter-
cellular adhesion molecule 1 (ICAM-1) in human micro-
vascular endothelial cell (HMVEC) lung tissue in 
comparison with serum from healthy controls or patients 
with other autoantibodies. Endothelial cell activation by 
increased ICAM-1 expression may contribute to the 
multiorgan involvement of myositis and ILD in anti-Jo-1-
positive patients [21]. Finally, in vitro studies demon-
strating the potential for anti-Jo-1 autoantibodies to 
induce type 1 interferon may suggest a direct pathogenic 
role in disease propagation [22].
Dermatomyositis clinical phenotypes
Anti-Mi-2
Targoﬀ   and Reichlin [23] ﬁ  rst described anti-Mi-2 auto-
antibodies in 9% of adult myositis patients and more 
speciﬁ   cally in 20% of adult DM patients. Subsequent 
studies on JDM cohorts have shown that anti-Mi-2 may 
also occur albeit at a lower frequency (4% to 10%) 
[7,24,25]. Th  is autoantibody has been associated with 
hallmark cutaneous DM lesions, including Gottron 
papules, heliotrope rash, cuticular overgrowth, and V-
sign and Shawl sign rashes. Love and colleagues [26] 
reported a correlation between UV radiation exposure at 
myositis onset and the development of anti-Mi-2 auto-
antibodies, suggesting an inﬂ   uence of environmental 
features on the development of autoimmunity in this 
syndrome. Interestingly, in vitro studies have demon  stra-
ted that the Mi-2 protein is upregulated in UV-irradiated 
human keratinocytes, further highlighting potential 
disease mechanisms [27]. Th   e autoantigen target, Mi-2, is 
a nuclear helicase protein that forms part of the 
nucleosome-remodeling deacetylase complex, which 
plays a role in gene transcription [28]. In work similar to 
studies on Jo-1 expression in target tissues, Mi-2 has 
been shown to be overexpressed in myositis muscle com-
pared with normal muscle and in particular is upregu-
lated in human DM myoﬁ   bers expressing markers of 
regeneration [17,29]. Functionally, Mi-2 has been shown 
to be essential for the repair of skin basal epidermis [30]; 
collectively, these data indicate that the autoantigen may 
have a role in the pathogenesis of disease.
Anti-p155/140 (TIF1-γ)
Autoantibodies to a 155-kDa protein (in most cases with 
a weaker 140-kDa band) and a 155-kDa/140-kDa 
complex were ﬁ  rst reported by Targoﬀ   and colleagues 
[31] and Kaji and colleagues [32]. Targoﬀ   and colleagues 
screened a cohort of 244 North American patients with 
IIM and found anti-p155/140 in 21% of the patients. 
Investigations into the clinical features of the anti-
p155/140-positive patients showed an association with 
DM and cancer and also demonstrated that Caucasian 
patients with anti-p155/140 autoantibodies had a unique 
HLA risk factor: DQA1*0301. Th   e parallel study by Kaji 
and colleagues screened 52 Japanese patients with DM 
along with healthy controls and disease controls. Th  e 
study found anti-p155/140 autoantibodies exclusively in 
13% of patients with DM. Clinical manifestations of the 
p155/140-positive DM patients, including the signiﬁ  cant 
association with malignancy as well as a more severe DM 
skin disease, were similar to those noted in the study by 
Targoﬀ    and colleagues. Th  e strong link with cancer-
associated myositis was conﬁ   rmed in a larger cohort 
study of Caucasian adult patients from the UK (Adult 
Onset Myositis Immunogenetic Collaboration [AOMIC] 
Figure 1. Immunoprecipitation of myositis-specifi  c 
autoantibodies. Ten percent SDS-PAGE of immunoprecipitates of 
[35S] labeled K562 cell extract. Lane 1: normal serum; lane 2: anti-
PL7; lane 3: anti-PL12; lane 4: anti-Zo; lane 5: anti-Jo-1; lane 6: anti-
OJ; lane 7: anti-KS; lane 8: anti Ha (unconfi  rmed); lane 9: anti-Mi-2; 
lane 10: anti-SRP; lane 11: anti-p155/140 (TIF1-γ); lane 12: anti-SAE; 
and lane 13: anti-p140 (NXP2). Myositis-specifi  c autoantibodies not 
shown include anti-EJ, anti p100/200, and anti-CADM-140 (MDA5). 
CADM, clinically amyopathic dermatomyositis; MDA5, melanoma 
diff  erentiation-associated gene 5; NXP2, nuclear matrix protein 2; 
SAE, small ubiquitin-like modifi  er activating enzyme 1 and 2; SRP, 
signal recognition particle; TIF1-γ, transcription intermediary factor 1 
gamma.
40 kDa
52 kDa
74 kDa
90 kDa
140 kDa
240 kDa
65 kDa
80 kDa
110 kDa
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155 kDa
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and colleagues [34] performed a meta-analysis of all 
published anti-p155/140 cohort studies to determine the 
accuracy of anti-p155/140 autoantibodies for predicting 
cancer in DM. Overall, anti-p155/140 autoantibodies 
have an 89% speciﬁ   city and a 70% sensitivity for 
predicting malignancy and have a negative predictive 
value of 93% and a diagnostic odds ratio of 18 [34].
Studies investigating the occurrence of anti-p155/140 
autoantibodies in JDM patients have also been com-
pleted. Gunawardena and colleagues [35] screened 116 
JDM cases by radiolabeled IPP and found anti-p155/140 
autoantibodies in 23% of the patients. Similarly, both 
Espada and colleagues [36] and Targoﬀ   and colleagues 
[31] have detected anti-p155/140 in 22% and 29% of patients 
with JDM, respectively. Interestingly, while the anti-
p155/140 autoantibody has been demonstrated by radio-
labeled immunodepletion experiments to target the same 
autoantigens as the adult anti-p155/140 auto  antibody, 
there are some clinical diﬀ  erences. In particular, cancer 
was not associated with anti-155/140-positive JDM cases; 
however, both anti-p155/140-positive adults and children 
appear to have a more severe cutaneous disease [35].
In preliminary work, the 155-kDa autoantigen target 
was identiﬁ  ed by immunoaﬃ   nity puriﬁ  cation and mass 
spectrometry as transcription intermediary factor 1 
gamma (TIF1-γ). Th   is was conﬁ  rmed by immunization of 
rabbits with a TIF1-γ peptide with aﬃ   nity puriﬁ  cation of 
subse  quent antibodies for use in sandwich enzyme-
linked immunosorbent assays (ELISAs) [37]. Th  e  identity 
of the autoantigen detected as the associated 140-kDa 
band has yet to be established, although this is likely to be 
a degradation product of TIF1-γ or possibly TIF1-α, an 
isoform that has a molecular weight of 140 kDa. TIF1-γ is 
a nuclear protein involved in con  trolling DNA trans-
cription. Moreover, TIF1-γ has been shown to inactivate 
Smad-4, which regulates trans  form  ing growth factor-
beta (TGF-β) signaling, thus promoting cell growth and 
diﬀ  erentiation (including malignant tumors) [38].
More recently, Hoshino and colleagues [39] developed 
a non-radiolabeled method for screening CTD patients 
for the presence of anti-p155/140. Biotinylated recom-
binant TIF1-γ was produced from a cDNA vector and 
used as the antigen source in a non-radiolabeled IPP 
assay. Comparisons between the results of this screen 
and standard radiolabeled IPP using HeLa cell lysates 
were similar, with 10 DM patients being positive in both 
assays, 68 DM patients being negative in both assays, and 
5 DM patients being positive in only one assay. Th  e 
authors suggested that the diﬀ  erences in results between 
the two assays might have been due to diﬀ  erences in 
conformation, protein stability, or other factors of the 
autoantigens. Interestingly, while the biotinylated assay 
may not have been as sensitive for the detection of weakly 
reactive anti-TIF1-γ autoantibodies, the detection of 
anti-TIF1-γ in cancer-associated DM was not reduced. 
Th   e introduction of this novel, non-radiolabeled assay may 
therefore be extremely helpful in the setting of routine 
laboratories for the screening of DM patients [39].
Anti-CADM-140 (MDA5)
Autoantibodies to a 140-kDa cytoplasmic protein in 
Japanese adult patients with clinically amyopathic 
dermato  myositis (CADM) were ﬁ  rst described by Sato 
and colleagues [40]. Th   is novel autoantibody was shown 
to be associated with rapidly progressive ILD. Further 
investigation in Asian adult cohorts of CTD patients has 
shown anti-CADM-140 to be speciﬁ  c for DM, with most 
having CADM [39,41,42]. Furthermore, anti-CADM-140 
has been associated with elevated serum ferritin con  cen-
trations, suggesting an association of anti-CADM-140 
and macrophage activation syndrome. Patients with 
CADM-140 autoantibodies have also been shown to have 
a poor prognosis; one study demonstrated that 46% of 
anti-CADM-140-positive patients died of respiratory 
failure within 6 months of disease onset [42].
Studies investigating p155/140 autoantibodies, anti-
CADM-140 autoantibodies, and anti-synthetase auto-
antibodies have shown that these autoantibodies are 
mutually exclusive [43]. Interestingly, while studies have 
shown that the incidence of ILD in CADM is greater in 
Asia, a systematic review of patients in North America 
and Europe has shown that approximately 15% of CADM 
patients develop ILD. Th   e prevalence of anti-CADM-140 
has been reported to be between 19% and 35% in 
Japanese patients with DM and between 53% and 73% in 
Japanese patients with CADM; however, to date, this 
autoantibody has not been des  cribed in European or 
American Caucasian cohorts, implying that either a 
genetic or an environmental factor is associated with 
anti-CADM-140 generation.
Th  e CADM-140 autoantigen has been identiﬁ  ed  as 
MDA5 from a cDNA expression library [41]. Th  is  protein 
is one of the retinoic acid-inducible gene-1-like receptors 
and has a role in the recognition of viral RNAs as part of 
the innate immune system. Th  e identiﬁ   cation of this 
autoantigen may therefore provide insight into the patho-
genesis of CADM and ILD and into the reported associa-
tion between viral infections and myositis. Th  e clinical 
utility and identity of this autoantigen have since been 
conﬁ  rmed in further studies by a combination of immuno-
aﬃ   nity chromatography with mass spectrometry analysis, 
by immunoblot with a commercial antibody, and by IPP 
with a biotinylated recombinant MDA5 protein [39,42].
Anti-p140 or anti-MJ (NXP-2)
A diﬀ  erent 140-kDa autoantigen target has also been des-
cribed in DM patients. Th   is autoantibody was origi  nally 
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patients with JDM [44]. In a preliminary study by Targoﬀ   
and colleagues [45], the MJ autoantigen was identiﬁ  ed as 
NXP2 (nuclear matrix protein 2, also known as MORC3) 
by means of a K562 cDNA expression library. Th  is 
protein is involved in transcriptional regulation [46]. 
Gunawardena and colleagues [47]  demonstrated that 
anti-p140 autoanti  bodies are a major serological subset 
in children recruited to the UK JDM Cohort Study. After 
IPP studies, 23% of 162 children were anti-p140-positive 
and had a higher incidence of calcinosis. Immuno-
depletion experiments using a commercial anti-NXP2 
antibody suggested that the p140 target in this study has 
the same identity as the MJ autoantigen. Recently, anti-
MJ was also described in 25% of an Argentinean juvenile 
IIM cohort and was associated with muscle contractures, 
atrophy, and signiﬁ  cant compromise of functional status 
[36]. Parallel studies on the European adult IIM cohort 
study (EuMyoNet) have also demon  strated the presence 
of what appears to be the same anti-p140 speciﬁ  city, 
which was found exclusively in 5% of DM patients. 
Preliminary data suggest that the clinical associations in 
adults diﬀ  er from JDM, with anti-p140 autoantibodies 
being associated with ILD in adults [48].
Anti-SAE
Betteridge and colleagues [49] ﬁ  rst described the presence 
of novel autoantibodies targeting 40-kDa and 90-kDa 
proteins in DM patients with similar clinical manifes  ta-
tions. Using IPP and mass spectrometry, the authors 
identiﬁ  ed these proteins as small ubiquitin-like modiﬁ  er 
activating enzyme 1 and 2 (SAE) that are involved in the 
post-translational modiﬁ   cation of numerous targets, 
including protein kinases and transcription factors [49]. 
Further work has conﬁ  rmed that anti-SAE was found in 
8% of DM patients from the AOMIC UK study. Th  e 
majority of anti-SAE patients presented with cutaneous 
manifestations and progressed to myositis with systemic 
features, including dysphagia. Th  is autoantibody was 
associated with a low frequency of malignancy and ILD. 
Furthermore, genetic studies found a strong association 
of the anti-SAE autoantibody with the HLA-DRB1*04 
DQA1*03 DQB1*03 haplotype [50]. Th  is autoantibody 
has also been investigated in the UK JDM Cohort and, 
with the exception of one patient, has not been seen in 
JDM (HG and ZEB, unpublished data).
Immune-mediated necrotizing myopathy
Anti-signal recognition particle
Autoantibodies to the signal recognition particle (SRP) 
were ﬁ  rst demonstrated in IIM by Reeves and colleagues 
[51]. SRP is a cytoplasmic protein with a role in the 
recog  nition and translocation of newly synthesized 
proteins across the endoplasmic reticulum. Anti-SRP 
auto  anti  bodies are present in approximately 5% of adult 
myositis patients and have been associated with acute-
onset severe necrotizing myopathy and with systemic 
features that may be refractory to standard immuno-
modulatory treatments [52-54]. Muscle biopsies from 
anti-SRP patients classically demonstrate muscle ﬁ  ber 
necrosis with minimal inﬂ  ammatory cell inﬁ  ltrate [53-
55]. Con  versely, anti-SRP autoantibodies are rarely 
detected in juvenile patients. A study by Rouster-Stevens 
and colleagues [56] detected anti-SRP in 3 of 123 children 
with clinical manifestations similar to those of anti-SRP 
adult patients. Interestingly, all of the anti-SRP-positive 
cases were of African-American origin, suggesting a 
speciﬁ  c immunogenetic association [56].
Anti-200/100
Th   e most recent myositis autoantibody to be described, 
by Christopher-Stine and colleagues [57], is the anti- 
200/100 autoantibody. Muscle biopsies from 225 myositis 
patients were screened for necrotizing myopathy 
features. Th  irty-eight patients demonstrated predomi-
nant necrosis without histological ﬁ  ndings of peri  fasci-
cular atrophy or red-rimmed vacuoles, and 26 of these 
patients had no known MSA. After radiolabeled IPP 
using HeLa cells, 16 (62%) of these MSA-negative 
patients were found to immunoprecipitate 200-kDa and 
100-kDa proteins. Since both of these proteins were 
immunoprecipitated together in all cases, the authors 
suggested that the subunits are likely to be part of the 
same protein complex. Th  is pattern was found in only 
one patient (from 187) without necrosis and in no healthy 
controls, indicating that this novel autoantibody is 
associated with immune-mediated necrotizing myopathy. 
Interestingly, 63% of patients with this autoantibody were 
found to have a history of exposure to statins. Further 
studies now need to be completed, identifying the 
200/100-kDa doublet, assessing the frequency of this 
autoantibody in additional cohorts, and clarifying the 
potential association of this autoantibody with statin 
exposure.
Conclusions
In this review, we have highlighted the recent studies 
identifying and characterizing novel myositis autoanti-
bodies and their associated autoantigens. Th  e  increasing 
number of patients with a known MSA aids the clinico-
serological classiﬁ   cation of myositis and may help to 
predict complications of disease, prognosis, and res-
ponses to treatment. Th  e identiﬁ   cation of these novel 
autoantibodies has lead to an increasing demand for the 
development of commercial assays in order to allow the 
screening of patients in the routine clinical setting. Th  e 
recent development and validation of a line blot assay 
containing a number of the MSAs demonstrate 
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currently in progress. Studies of MSAs and their 
corresponding targets have also provided insights into 
the pathogenesis of IIM, and links between environ-
mental, immunogenetic, and autoantibody status have 
been described. Further studies are now required to 
identify novel targets in patients who are currently 
viewed as autoantibody-negative and to further elucidate 
the role of autoimmunity in the pathophysiology of IIM 
subtypes.
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